

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

SAFETY DATA SHEET

Section 1: Identification	
Section 1, Identification	
GHS Product identifier	Tadalafil USP 2.5mg, 5 mg, 10 mg and 20 mg
Other means of identification Item Code	Tadalafil, Finished product specification
Recommended use	Pharmaceutical
	Hetero Labs Limited, Unit III, Plot No. 22-110,
Manufacturer	Part-II, IDA, Jeedimetla, Hyderabad 500055,
	Telangana, India (IND).
Distributor	Camber Pharmaceuticals, Inc., Piscataway, NJ,
Costing 2: Harand/a) Identification	08854.
Section 2: Hazard(s) Identification	
Section 2, Hazard(s)identification	Not classified
Physical hazards	Not classified
Health hazards	Not classified
OSHA defined hazards	
Label elements	None
	None
Hazard symbol	The mixture does not meet the criteria for
Signal word	classification
Hazard statement	Not available
Precautionary statement	
Prevention	Not available
Barramas	Not available
Response	Not available
Storage	None known
Disposal	
•	None
Hazard(s) not otherwise classified (HNOC)	
Supplemental information	
Section 3: Composition/Information on Ingre	edients edients
Mixtures	



Chemical name	Common nar	ne and synonyms	CAS number	%	
Tadalafil	methyl-2,3,6,7,12	-Benzodioxol-5-yl)-2- 2,12a-hexahydro-2- 1',2':1,6]pyrido[3,4- ne	171596-29-5		
Composition comments		onents of this product a		s and/or	
Section 4: First-Aid Measure	es				
Inhalation		Remove to fresh air. If breathing stops, provide artificial respiration. Get medical attention immediately			
Skin Contact		Wash off immediately with plenty of water. Continue to rinse for at least 15 minutes. Immediately take off all contaminated clothing. Get medical attention if irritation develops and persists			
Eye Contact		In case of eye contact, remove contact lens and rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention			
Ingestion		Immediately give large quantities of water to drink. Never give anything by mouth to a victim who is unconscious or is having convulsions. Call a physician immediately			
Most important symptoms/effects, acute and delayed		Headache. Flushing			
Symptoms/effects, acute an	Symptoms/effects, acute and delayed				
Indication of immediate medical attention and special treatment needed		PRE-EXISTING MEDICAL CONDITIONS WHICH MAY BE AGGRAVATED BY EXPOSURE: Individuals on nitrate or alpha blocker therapy			
General information		Intact capsules or tablets are not considered hazardous under normal handling procedures. The recommendations in this section are intended for manufacturing or other situations where exposure to contents may occur			



Section 5: Fire-Fighting Measures				
Section 5, Fire-fighting measures				
Suitable extinguishing media	Carbon dioxide, dry chem	ical or water		
Unsuitable extinguishing media	None known			
Specific hazards arising from the c	hemical intended for manufactur	The recommendations in this section ar intended for manufacturing or other situation where exposure to contents may occur		
Special protective equipment	Wear self-contained bre	athing apparatus and		
and precautions for firefighters	protective clothing			
Section 6: Accidental Release Meas	sures			
Section 6, Accidental release meas	ures			
Personal precautions, protective equipment and emergency procedures	Wear suitable protective eye/face protection. See for Personal Protective Ed	Section 8 of the SDS		
Environmental precautions	Avoid discharge into dra onto the ground	ins, water courses or		
Methods and materials for containment and cleaning up	intended for manufactur where exposure to conte sweep. Collect spill using a HEPA filter. Be aware explosion when using e vacuum is not availa			
Section 7: Handling and Storage				
Section 7, Handling and storage				
Precautions for safe handling	Wash hands thoroughly a	Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling. See Section 8 of the SDS for Personal Protective Equipment		
Conditions for safe storage,	Store at 20° to 25°C (68° t	o 77°F) [see USP		
including any incompatibilities	Controlled Room Temperature]. Keep out of reach of children			
Section 8: Exposure Controls/Perso	onal Protection			
Section 8, Exposure controls/perso	Section 8, Exposure controls/personal protection			
Occupational exposure limits (Lilly (LEG))				
Components	Туре	Value		



T	TWA (12hrs)	13 ug/m3	
Tadalafil (CAS 171596-29-5)	TWA (8hrs)	20 ug/m3	
Biological limit values	No biological exposure lim	nits noted for the	
	ingredient(s).		
Appropriate engineering	Intact capsules or tablet	s are not considered	
controls	hazardous under normal	• ,	
	and protective equipmen	•	
	recommendations in this		
	for manufacturing or ot		
	exposure to contents may	occur.	
	Open handling is not	recommended. Use	
	appropriate control mea	asures such as fume	
	hood, ventilated enclosu	re, isolator (i.e. glove	
	bag/glove box) and/or	closed transfers to	
	maintain airborne levels	s below occupational	
	exposure level (OEL).		
•	uch as personal protective equipment		
Eye/face protection	Safety glasses with side sh		
	If splash potential or dusty	y operations, wear	
	goggles/faceshield.		
Skin protection	Tat		
Hand protection	Chemical Hand protection	-	
Other	Chemical-resistant gloves	•	
Pagnington, protection	body covering to minimize		
Respiratory protection	If the applicable occupation (OEL) is anticipated to be	•	
	approved respirator with		
	factor to control exposure	-	
Thermal hazards	Not available		
General hygiene considerations	Facine sains sentuals als	عالم المالية	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Engineering controls sho		
	primary means to control Follow good workplace h	· · ·	
	as washing hands after ha	, ,	
	_		
Section 9: Physical and Chemical P			
Section 9, Physical and chemical p	roperties		
Appearance			



Physical State	Solid
Form	Tablet
Colour	2.5 mg: Blue, 5 mg/10 mg/ 20 mg: White
Description	·
	Tadalafil tablets USP, 2.5 mg are blue color,
	round shaped, biconvex, film-coated tablets
	debossed with 'T18' on one side and 'H' on the
2.5 mg	other side.
	Bottles of 30 tablets NDC 31722-643-30
	Carton of 30 (3×10) NDC 31722-643-31
	unit-dose tablets
	Tadalafil tablets USP, 5 mg are white color, round
	shaped, biconvex, film-coated tablets debossed
	with 'T17' on one side and 'H' on the other side.
5 mg	Bottles of 30 tablets NDC 31722-644-30
	Carton of 30 (3×10) NDC 31722-644-31
	unit-dose tablets
	Tadalafil tablets USP, 10 mg are white color,
	capsule shaped, biconvex, film-coated tablets
	debossed with 'T16' on one side and 'H' on the
10 mg	other side.
8	Bottles of 30 tablets NDC 31722-645-30
	Carton of 100 (10×10) NDC 31722-645-31
	unit-dose tablets
	Tadalafil tablets USP, 20 mg are white color,
	capsule shaped, biconvex, film-coated tablets
20 mg	debossed with 'T15' on one side and 'H' on the
	other side.
	other side.



		Bottle	s of 30 tablets	NDC 31722-6	46-30
		Cartor	n of 100 (10×10)	NDC 31722-6	646-31
		unit-d	ose tablets		
Section 10: Stability and Reactivit	у				
Section 10, Stability and reactivity	/				
Reactivity	Reactivity		ater reactive		
Chemical stability		Mater	ial is stable under r	normal conditio	ns
Possibility of hazardous reactions	5	Hazar	dous polymerizatio	n does not occı	ır
Conditions to avoid		None	known		
Incompatible materials		Strong	g oxidizing substand	ces	
Hazardous decomposition produc	cts		Hazardous decomposition products formed under fire conditions		
Section 11: Toxicological Information	Section 11: Toxicological Information				
Information on likely routes of ex	cposure				
Acute toxicity					
			_		
Components	Specie	es .	Tes	st Results	
Tadalafil (CAS 171596-29-5)	Specie	es	Tes	st Results	
Tadalafil (CAS 171596-29-5) Acute	Specie	es .	Tes	st Results	
Tadalafil (CAS 171596-29-5) Acute Dermal	Specie Rabbi		> 1000 mg/kg No		oxicity
Tadalafil (CAS 171596-29-5) Acute Dermal					oxicity
Tadalafil (CAS 171596-29-5) Acute Dermal				mortality. No to	
Tadalafil (CAS 171596-29-5) Acute Dermal LD Oral	Rabbi		> 1000 mg/kg No > 2000 mg/kg No > 62.5 mg/kg (Inti	mortality. No to	oxicity
Tadalafil (CAS 171596-29-5) Acute Dermal LD Oral LD	Rabbi Rat Rat	t	> 1000 mg/kg No > 2000 mg/kg No > 62.5 mg/kg (Inti- Convulsions	mortality. No to	oxicity
Tadalafil (CAS 171596-29-5) Acute Dermal LD Oral LD Other	Rabbi Rat Rat Rat Rabbit: Sligl	t nt irrita	> 1000 mg/kg No > 2000 mg/kg No > 62.5 mg/kg (Inti- Convulsions	mortality. No to mortality. No to ravenous) No m	oxicity oortality.
Tadalafil (CAS 171596-29-5) Acute Dermal LD Oral LD Other LD	Rabbi Rat Rat Rabbit: Sligl Based on av	t ht irrita vailable tly irrita	> 1000 mg/kg No > 2000 mg/kg No > 62.5 mg/kg (Interconvulsions) tion. data, the classification	mortality. No to mortality. No to ravenous) No m	oxicity nortality.
Tadalafil (CAS 171596-29-5) Acute Dermal LD Oral LD Other LD Skin corrosion/irritation Serious eye damage/eye	Rabbi Rat Rat Rabbit: Sligl Based on av	t ht irrita vailable tly irrita	> 1000 mg/kg No > 2000 mg/kg No > 62.5 mg/kg (Interconvulsions tion. data, the classificating.	mortality. No to mortality. No to ravenous) No m	oxicity nortality.
Tadalafil (CAS 171596-29-5) Acute Dermal LD Oral LD Other LD Skin corrosion/irritation Serious eye damage/eye irritation	Rabbi Rat Rat Rabbit: Sligl Based on ava	t vailable tly irrita	> 1000 mg/kg No > 2000 mg/kg No > 62.5 mg/kg (Interconvulsions tion. data, the classificating.	mortality. No to mortality. No to ravenous) No mortality are to criteria are	oxicity nortality.



Germ cell mutagenicity	Result in genetic toxicity assays (in vitro and in vivo): Negative Based on available data, the classification criteria are not met	
Carcinogenicity	Not listed by ACGIH, IARC, NIOSH, NTP OR OSHA. Based on available data, the classification criteria are not met	
IARC Monographs. Overall Evaluation of Carcinogenicity	Not available	
OSHA Specifically Regulated Substances (29 CFR 1910.1001- 1050)	Not listed	
US. National Toxicology Program (NTP) Report on Carcinogens	Not available	
Reproductive toxicity	There was no impairment of fertility in male and female rats. In beagle dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day and above, there were alterations to the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs. These findings were not observed in rats or mice. Furthermore, in men taking tadalafil 10 or 20 mg/daily for 6 months, there were no clinically relevant effects on sperm concentration, count, motility, or morphology. Additionally, there were no significant effects of serum levels of testosterone, luteinizing hormone, or follicle stimulating hormone. There was no evidence of teratogenicity, embryotoxicity or fetotoxicity in rats or mice that received up to 1000 mg/kg/day. In a rat pre- and postnatal development study, the observed no effect dose was 30 mg/kg/day. Based on available data, the classification criteria are not met.	
Specific target organ toxicity - single exposure	Due to lack of data the classification is not possible	
Specific target organ toxicity - repeated exposure	Repeated oral doses of tadalafil for more than six months resulted in decreased testicular weight in dogs. The decreased testes weights (reported at doses of 25 mg/kg/day and above in the 12-month study) correlated with degeneration and atrophy of the seminiferous epithelium. Decreased sperm in the epididymes was also reported with aspermia in the most severely affected dogs. No effects on semen parameters reported in humans after sixmonths of daily dosing (10 or 20 mg/day).	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

		When administered orally for 5 or 28 days at 5 mg/kg/day, blood pressure was reduced in rats. No significant findings were reported in rats or mice administered up to 800 mg/kg by oral gavage for up to 3 months. Based on available data, the classification criteria are not met.			
Aspiration hazard		Not applicable			
Further information		Based on animal studies with Tadalafil, chronic overexposure by ingestion may cause testicular tissue changes and decreased sperm production. However, two six-month human clinical studies reported no changes in sperm parameters. The most common adverse effects related to drug treatment were headache, lower back pain, and vasodilation (flushing), which can result in transient decreases in blood pressure			
Section 12: Ecolog	gical Information				
Ecotoxicity : Harn	nful to aquatic life	e with long lasting effects.			
Comp	onents	Species	Test results		
Tadalafil (CAS 17	'1596-29-5)				
Acute	EC50	> 1000 mg/l, 3 hr (Respiration inl sludge)	nibition of activated		
Other Chronic	EC50	Pseudokirchnerella subcapitata	> 1200 µg/l, 72 hr (yield) 1000 mg/l, 3 hr (Respiration inhibition of activated sludge) (highest concentration		
			tested)		
		Chironomous riparius (sediment	dwelling 250 mg/kg, 28 d		
Other	NOEC	(sediment exposure) midge) Pseudokirchnerella subcapitata	> 1200 µg/l, 72 hr (average specific growth rate) (highest concentration tested)		
Aquatic Acute Chronic			300 μg/l, 72 hr (yield)		

Daphnia magna

EC50

Crustacea

> 2000 mg/l, 48 hr



	NOEC	Daphnia magna	1200 μg/l, 21 d (Full Life-Cycle Toxicity)
Fish	LC50	Rainbow trout, donaldson trout (Oncorhynchus mykiss)	> 2100 μg/l, 96 hr
Chronic Acute			
Crustacea	LOEC	Daphnia magna	1200 μg/l, 21 d (Full Life-Cycle Toxicity) 2000 μg/l, 48 hr
	NOEC	Daphnia magna	(highest concentration tested)
Fish	NOEC	Fathead minnow (Pimephales promelas)	1200 μg/l (embryo and 28 days post hatch) (highest concentration tested)
		Rainbow trout, donaldson trout (Oncorhynchus mykiss)	2100 µg/l, 96 hr (highest concentration tested)
Persistence and de	egradability	tested)	
Bioaccumulative p	otential	total suspended solids/L): none No data available on bioaccumula	ation.



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Partition coefficient n-octanol / water (log Kow)

Tadalafil 2.32

Mobility in soil No data available

Adsorption (Soil/sediment sorption - log Koc)

Tadalafil 1.95

Other adverse effects Not available

Ecotoxicological Properties

Drinking Water

Components Test Results

Tadalafil 2.5 μg/l, (Lilly Aquatic Exposure Guideline)

Chronic Exposure of Aquatic Organisms

Components Test Results

Tadalafil 200 μg/l, (Lilly Aquatic Exposure Guideline)

Acute Exposure of Aquatic Organisms

Components Test Results

Tadalafil 1000 μg/l, (Lilly Aquatic Exposure Guideline)

Section 13: Disposal Considerations		
Disposal instructions	Dispose in accordance with all applicable	
	Disposal instructions regulations.	
Section 14: Transport Information		
DOT	Not regulated as dangerous goods	
IATA	Not regulated as dangerous goods	
IMDG	Not regulated as dangerous goods	
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not available	
Section 15: Regulatory Information		
US federal regulations	This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200. One or more components are not listed on TSCA.	
US federal regulations TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)	Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200. One or more components are not listed on	
TSCA Section 12(b) Export Notification (40	Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200. One or more components are not listed on TSCA.	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

OSHA Specifically Regulated S CFR 1910.1001-1050)	Substances (29	Not listed		
Superfund Amendments and Reauthorization Act of 1986 (SARA)				
Hazard categories		Immediate Hazard - No		
		Delayed Hazard - No		
		Fire Hazard - No		
		Pressure Hazard - No		
		Reactivity Hazard - No	<u> </u>	
SARA 313 (TRI reporting)		Not regulated		
Other federal regulations				
Clean Air Act (CAA) Section 1	12 Hazardous	Not regulated		
Air Pollutants (HAPs) List		Not regulated		
Clean Air Act (CAA) Section 1 Release Prevention (40 CFR 6	• •	Not regulated		
Safe Drinking Water Act (SDV	VA)	Not regulated		
		California Safe Drir	nking Water and Toxic	
		Enforcement Act of 1	986 (Proposition 65): This	
US state regulations		material is not knowr	to contain any chemicals	
_		currently listed as ca	rcinogens or reproductive	
		toxins		
US. California Controlled Substances. CA				
Department of Justice (California Health and		Not listed		
Safety Code Section 11100)				
US. Massachusetts RTK - Sub	stance List	Not regulated		
US. New Jersey Worker and C	Community	Not listed		
Right-to-Know Act		Not listed		
US. Pennsylvania Worker and Community Right-to-Know Law		Not listed		
US. Rhode Island RTK		Not regulated		
US. California Proposition 65		Not Listed		
International Inventories				
Country(s) or region	Inver	ntory name	On inventory (yes/no)*	
Canada	Domestic Substances List (DSL)		No	
Canada	Non-Domestic S	ubstances List (NDSL)	No	
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory		No	
*A "Yes" indicates that all compared by the governing of	•	uct comply with the inven	tory requirements	

A "No" indicates that one or more components of the product are not listed or exempt from listing on

the inventory administered by the governing country(s).



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Section 16: Other information, including date of preparation or last revision

Issue Date: 14-03-2019

Version: 00

Revision note: New

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Labs Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Labs Limited reserves the right to revise this SDS.